These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19580952)

  • 61. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
    Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
    [No Abstract]   [Full Text] [Related]  

  • 62. Why and when to implement incretin therapy.
    Freeman JS; Unger J
    J Fam Pract; 2008 Sep; 57(9 Suppl):S19-25. PubMed ID: 18786340
    [No Abstract]   [Full Text] [Related]  

  • 63. Redefining insulin therapy in type 2 diabetes mellitus.
    Rosenstock J
    Postgrad Med; 2004 Nov; 116(5 Suppl Exploring):21-9. PubMed ID: 19667676
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Incretin-based therapy for diabetic ulcers: from bench to bedside.
    Ku HC; Liang YJ
    Expert Opin Investig Drugs; 2018 Dec; 27(12):989-996. PubMed ID: 30449201
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes.
    Jones MR; Mudaliar S; Hernandez-Triana E; Unnikrishnan AG; Lai YL; Abby SL; Misir S; Jin X; Nagendran S
    Curr Med Res Opin; 2009 Sep; 25(9):2239-49. PubMed ID: 19622007
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Introduction: Evaluating the role of incretin-based therapies in the management of type 2 diabetes.
    Am J Manag Care; 2011 Mar; 17(2 Suppl):S39-40. PubMed ID: 21528614
    [No Abstract]   [Full Text] [Related]  

  • 68. A checklist approach to selecting the optimal treatment regimen for a patient with type 2 diabetes.
    Peterson GE
    J Fam Pract; 2009 Sep; 58(9 Suppl Treating):S21-5. PubMed ID: 19744421
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pharmacist roles in the management of patients with type 2 diabetes.
    Sisson E; Kuhn C
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S41-5. PubMed ID: 19801364
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Clinical studies that have influenced the treatment of diabetes].
    Olsovský J
    Vnitr Lek; 2009 Apr; 55(4):349-53. PubMed ID: 19449748
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects.
    Steinert RE; Poller B; Castelli MC; Friedman K; Huber AR; Drewe J; Beglinger C
    Clin Pharmacol Ther; 2009 Dec; 86(6):644-50. PubMed ID: 19727071
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Emerging therapies for metabolic diseases--the focus is on diabetes and obesity.
    Hughes TE
    Curr Opin Chem Biol; 2009 Jun; 13(3):332-7. PubMed ID: 19482541
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Dipeptidyl-peptidase-4 inhibitors for treatment of type 2 diabetes.
    Kripke C
    Am Fam Physician; 2009 Mar; 79(5):372. PubMed ID: 19275065
    [No Abstract]   [Full Text] [Related]  

  • 74. The stomach in diabetes: from villain to ally.
    Camilleri M
    Clin Gastroenterol Hepatol; 2009 Mar; 7(3):285-7. PubMed ID: 19049906
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Piperidinyl-2-phenethylamino inhibitors of DPP-IV for the treatment of type 2 diabetes.
    Benbow JW; Andrews KA; Aubrecht J; Beebe D; Boyer D; Doran S; Homiski M; Hui Y; McPherson K; Parker JC; Treadway J; Vanvolkenberg M; Zembrowski WJ
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2220-3. PubMed ID: 19285862
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Engineering Skin with Skinny Genes.
    Böttcher A; Lickert H; Tschöp M
    Cell Stem Cell; 2017 Aug; 21(2):153-155. PubMed ID: 28777938
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A New Dawn for the Treatment of Type 2 Diabetes: Integrating Incretin Mimetics Into Clinical Practice.
    J Am Acad Nurse Pract; 2007 Nov; 19(s1):1-24. PubMed ID: 18307618
    [No Abstract]   [Full Text] [Related]  

  • 78. Diabetes (III): New Hormones Promise More Effective Therapy.
    Maugh TH
    Science; 1975 May; 188(4191):920-3. PubMed ID: 17749809
    [No Abstract]   [Full Text] [Related]  

  • 79. Correction to: Breast cancer, diabetes mellitus and glucagon‑like peptide‑1 receptor toward exploring their possible associations.
    Hashimoto Takigami N; Kuniyoshi S; Miki Y; Tamaki K; Kamada Y; Uehara K; Tsuchiya S; Terukina S; Iwabuchi E; Kanai A; Miyashita M; Ishida T; Tamaki N; Sasano H
    Breast Cancer Res Treat; 2022 Jan; 191(1):221. PubMed ID: 34606001
    [No Abstract]   [Full Text] [Related]  

  • 80. Associations between time in range and insulin secretory capacity in Japanese patients with type 2 diabetes.
    Tanaka K; Okada Y; Uemura F; Tanaka Y
    Sci Rep; 2024 Jun; 14(1):12910. PubMed ID: 38839813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.